Abstract: The subject of the invention is the application of CXCL12 (Chemokine (C-X-C motif) Ligand 12) and IGFBP2 inhibitors for the treatment of diabetes mellitus associated pancreatic cancer. The core of this invention is the discovery that the chronically increased glucose levels (chronic hyperglycemia) could may an important role in the development of the pancreatic cancer and that the development of the pancreatic cancer due to chronic hyperglycemia or an already developed pancreatic cancer may be prevented/inhibited/delayed by the inhibition of CXCL12 and IGFBP2. In addition the subject of the invention is the production of inhibitors for the application as a treatment of diabetes mellitus associated pancreatic cancer and pharmaceutical drugs containing the inhibitors.